The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance

innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer